Medical Advances Account For Half Of CDER 2013 NMEs
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Fourteen first-in-class and advance-in-class NMEs were approved by CDER in 2013, accounting for 52% of new drug approvals. The most innovative drugs represent a lower share of approvals in 2013 compared with recent years, but the total of nine first-in-class NMEs is in line with the 25-year average.
You may also be interested in...
More Me-Too Drugs Please, FDA’s Jenkins Asks Industry
FDA’s top new drug official called out industry’s innovation model, noting that major primary care markets are being left underserved as sponsors focus on precision medicine and rare diseases.
What Innovation Crisis? First-In-Class Drug Approvals Stable For Almost 25 Years, FDA Says
An FDA study evaluating NMEs by level of innovation finds level first-in-class approvals to be consistent, and approvals after the study period reinforce “encouraging” findings. Analysis says new metric should be basis for assessment of programs created by FDASIA to speed development of innovative products.
Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116
As Merck’s 21-valent vaccine approaches its 17 June user fee goal, the US CDC’s vaccine committee is looking at new adult age-based recommendations and bracing for a full pipeline led by GSK’s 24-valent candidate.